Context Bladder cancer has become a common cancer globally, with an estimated 430 000
new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer …

Context Due to high recurrence rates, intensive surveillance strategies, and expensive
treatment costs, the management of bladder cancer contributes significantly to medical …

Urinalysis is attractive in non‐invasive early diagnosis of bladder cancer compared with
clinical gold standard cystoscopy. However, the trace bladder tumor biomarkers in urine and …

In Europe, an estimated 151 297 new cases of bladder cancer were diagnosed in 2012, with
an age-standardised incidence rate (per 100000 persons) of 17.7 for males and 3.5 for …

Purpose: To characterize immune cell expression among patients with non–muscle invasive
bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG). Experimental Design …

Abstract Background Circular RNAs (circRNAs) circularized by back-splicing of pre-mRNA
are widely expressed and affected the proliferation, invasion and metastasis of bladder …

The purpose of this paper is to provide a current view of the economic burden of bladder
cancer, with a focus on the cost effectiveness of available interventions. This review updates …

Simple Summary The clinical management of bladder cancer has been developing in the
past decade, including diagnostic tools and treatment options. Both monotherapy and …

Context The role of surgery in metastatic bladder cancer (BCa) is unclear. Objective In this
collaborative review article, we reviewed the contemporary literature on the surgical …

Objectives With the advent of novel genomic and transcriptomic technologies, new urinary
biomarkers have been identified and tested for bladder cancer (BCa) surveillance. To …